- Full Year 2024 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2024
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2024
- Q3 2024 Eisai Co Ltd Earnings Presentation TranscriptFeb 06, 2024
- Eisai Co Ltd Launch of LEQEMBI in Japan TranscriptDec 13, 2023
- Q2 2024 Eisai Co Ltd Earnings Presentation TranscriptNov 07, 2023
- Q1 2024 Eisai Co Ltd Earnings Presentation TranscriptAug 02, 2023
- Eisai Co Ltd Media and Investor Conference TranscriptJul 07, 2023
- Full Year 2023 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2023
- Eisai Co Ltd Information Meeting TranscriptMar 10, 2023
- Q3 2023 Eisai Co Ltd Earnings Call TranscriptFeb 06, 2023€52.72 (-4.97%)Earnings
- Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing TranscriptJan 07, 2023
- Eisai Co Ltd Clarity AD Study Briefing TranscriptNov 30, 2022
- Q2 2023 Eisai Co Ltd Earnings Call TranscriptNov 07, 2022€59.02 (-1.99%)Earnings
- Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call TranscriptSep 28, 2022
- Q1 2023 Eisai Co Ltd Earnings Call TranscriptAug 05, 2022€43.78 (-1.42%)Earnings
- Full Year 2022 Eisai Co Ltd Earnings Presentation TranscriptMay 13, 2022
- Eisai Co Ltd Information Meeting TranscriptMar 16, 2022
- Q3 2022 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2022€44.4 (-1.33%)Earnings
- Q2 2022 Eisai Co Ltd Earnings Call TranscriptNov 01, 2021€63 (+5.00%)Earnings
- Q1 2022 Eisai Co Ltd Earnings Call TranscriptAug 04, 2021€69.5Earnings
- Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation TranscriptJun 09, 2021
- Full Year 2021 Eisai Co Ltd Earnings Call TranscriptMay 12, 2021€52.5 (-0.94%)Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 26, 2021
- Q3 2021 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2021€60 (-0.83%)Earnings
- Q2 2021 Eisai Co Ltd Earnings Call TranscriptNov 05, 2020€94 (+24.50%)Earnings
- Q1 2021 Eisai Co Ltd Earnings Call TranscriptAug 03, 2020€70 (+2.94%)Earnings
- Full Year 2020 Eisai Co Ltd Earnings Call TranscriptMay 13, 2020€63.5 (-1.55%)Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 06, 2020
- Q3 2020 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptJan 31, 2020
- Full Year 2019 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptMay 13, 2019
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2019
Q1 2021 Eisai Co Ltd Earnings Call Transcript
Thank you this is Yanagi, CFO, speaking about financial part. Please look at Page 2. Here, you see the consolidated statement of income or P&L for the first quarter. Based on our Partnership model, we have overcome the impact by COVID-19. We have exceeded plan and achieved increase in both revenue and profit. Top line revenue was JPY 165.6 billion, up 8% from a year earlier. There were impacts of COVID-19, drug price revision in Japan and foreign exchange rates, which was partly offset by royalty for tazemetostat and core growth driver, LENVIMA, increased revenue by JPY 10 billion, leading to 8% increase in revenue from a year earlier.
LENVIMA profitability is very high. That is to say, cost ratio is very low. And together with the business development projects, cost ratio has been reduced to 23.1%.
Gross profit was JPY 127.3 billion, up 15% from a year earlier, with double-digit growth. And this total expenses increase was contained within the increase in the gross profit, therefore, leading to a significant increase in profit
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)